REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Clinical trials for REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy targets Hard-to-Cure leukemia in early trial
Disease control OngoingThis early-stage study tests whether adding immune-boosting drugs (nivolumab and ipilimumab) to blinatumomab can help people with a severe form of B-cell leukemia that has returned or not responded to treatment. The main goals are to find safe doses and understand side effects. A…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
Promising combo targets Hard-to-Treat leukemia
Disease control OngoingThis study tests a new combination of two drugs—venetoclax and vincristine—in adults with acute lymphoblastic leukemia (ALL) that has returned or not responded to prior therapy. The goal is to find the safest dose and see if the combination can help more patients achieve remissio…
Matched conditions: REFRACTORY B ACUTE LYMPHOBLASTIC LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 26, 2026 19:37 UTC